[go: up one dir, main page]

EP4284824A4 - Chimeric antigen receptors targeting cd20 - Google Patents

Chimeric antigen receptors targeting cd20

Info

Publication number
EP4284824A4
EP4284824A4 EP22746521.8A EP22746521A EP4284824A4 EP 4284824 A4 EP4284824 A4 EP 4284824A4 EP 22746521 A EP22746521 A EP 22746521A EP 4284824 A4 EP4284824 A4 EP 4284824A4
Authority
EP
European Patent Office
Prior art keywords
chimeric antigen
antigen receptors
receptors targeting
targeting
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22746521.8A
Other languages
German (de)
French (fr)
Other versions
EP4284824A2 (en
Inventor
Yihong Yao
Jiaqi Huang
Xin Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abelzeta Inc
Original Assignee
Abelzeta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/352,915 external-priority patent/US11472858B2/en
Application filed by Abelzeta Inc filed Critical Abelzeta Inc
Publication of EP4284824A2 publication Critical patent/EP4284824A2/en
Publication of EP4284824A4 publication Critical patent/EP4284824A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP22746521.8A 2021-01-27 2022-01-26 Chimeric antigen receptors targeting cd20 Pending EP4284824A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163142216P 2021-01-27 2021-01-27
US202163154040P 2021-02-26 2021-02-26
US17/352,915 US11472858B2 (en) 2017-02-08 2021-06-21 Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
PCT/US2022/013875 WO2022164886A2 (en) 2021-01-27 2022-01-26 Chimeric antigen receptors targeting cd20

Publications (2)

Publication Number Publication Date
EP4284824A2 EP4284824A2 (en) 2023-12-06
EP4284824A4 true EP4284824A4 (en) 2025-03-12

Family

ID=82654878

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22746521.8A Pending EP4284824A4 (en) 2021-01-27 2022-01-26 Chimeric antigen receptors targeting cd20

Country Status (2)

Country Link
EP (1) EP4284824A4 (en)
WO (1) WO2022164886A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. CANCER TREATMENT BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
CN120058944A (en) 2019-01-30 2025-05-30 真和制药有限公司 Anti-GAL3 antibodies and uses thereof
MX2022014786A (en) 2020-05-26 2023-01-16 Truebinding Inc Methods of treating inflammatory diseases by blocking galectin-3.
CN120641113A (en) 2023-03-31 2025-09-12 西比曼生物科技集团 Bispecific chimeric antigen receptor targeting CD20 and BCMA
AU2024286886A1 (en) * 2023-06-09 2025-12-11 Antengene Biologics Limited Novel antibodies targeting cd3 and another target and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108285486A (en) * 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 Using CD20 as the specific antibody of target spot, CAR-NK cells and its preparation and application
WO2018145649A1 (en) * 2017-02-08 2018-08-16 西比曼生物科技（上海）有限公司 Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof
WO2020151752A1 (en) * 2019-01-22 2020-07-30 亘喜生物科技（上海）有限公司 Engineered immune cells targeting cd20 combination

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018145649A1 (en) * 2017-02-08 2018-08-16 西比曼生物科技（上海）有限公司 Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof
CN108285486A (en) * 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 Using CD20 as the specific antibody of target spot, CAR-NK cells and its preparation and application
WO2020151752A1 (en) * 2019-01-22 2020-07-30 亘喜生物科技（上海）有限公司 Engineered immune cells targeting cd20 combination

Also Published As

Publication number Publication date
WO2022164886A3 (en) 2022-09-09
EP4284824A2 (en) 2023-12-06
WO2022164886A2 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
EP4284824A4 (en) Chimeric antigen receptors targeting cd20
IL276396B2 (en) Chimeric antigen receptors targeting cd70
AU2021393434A9 (en) Bcma-targeted chimeric antigen receptors
SG11202108759SA (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof
AU2021330958A9 (en) Bcma chimeric antigen receptors
EP4013798A4 (en) Chimeric antigen receptors and uses thereof
IL307408A (en) Chimeric antigen receptors for targeting CD5 positive cancer
IL316102A (en) Chimeric antigen receptor for tumor targeting
AU2021368741A9 (en) Dual targeting chimeric antigen receptors
EP4237543A4 (en) Dual targeting chimeric antigen receptors
EP4126925A4 (en) Chimeric antigen receptors targeting cd33
EP4323387A4 (en) Improved chimeric antigen receptors and uses thereof
EP4225799A4 (en) Cd19-directed chimeric antigen receptor constructs
HK40099025A (en) Chimeric antigen receptors targeting cd20
HK40100719A (en) Dual targeting chimeric antigen receptors
HK40117252A (en) Chimeric antigen receptors
HK40103037A (en) Bcma-targeted chimeric antigen receptors
HK40105054A (en) Ror1 targeting chimeric antigen receptor
HK40068583A (en) Antibodies against 4g7-derived chimeric antigen receptors
HK40091272A (en) Novel constructs for chimeric antigen receptors
HK40102923A (en) Prostate cancer chimeric antigen receptors
AU2019904237A0 (en) Chimeric Antigen Receptors
HK40119844A (en) Chimeric antigen receptor for tumor targeting
GB202004404D0 (en) Chimeric antigen receptors
HK40112045A (en) Anti-trem2 chimeric antigen receptor

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230824

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40099025

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABELZETA INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0783 20100101ALI20241030BHEP

Ipc: A61K 39/00 20060101ALI20241030BHEP

Ipc: A61P 35/00 20060101ALI20241030BHEP

Ipc: A61K 35/17 20150101ALI20241030BHEP

Ipc: C07K 16/28 20060101ALI20241030BHEP

Ipc: C07K 14/725 20060101AFI20241030BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20250210

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0783 20100101ALI20250204BHEP

Ipc: A61K 39/00 20060101ALI20250204BHEP

Ipc: A61P 35/00 20060101ALI20250204BHEP

Ipc: A61K 35/17 20150101ALI20250204BHEP

Ipc: C07K 16/28 20060101ALI20250204BHEP

Ipc: C07K 14/725 20060101AFI20250204BHEP